{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T21:05:52Z","timestamp":1790888752797,"version":"4.1.0"},"reference-count":29,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","japha.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Pharmacists Association"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1016\/j.japh.2019.06.012","type":"journal-article","created":{"date-parts":[[2019,7,16]],"date-time":"2019-07-16T20:24:32Z","timestamp":1563308672000},"page":"698-703","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["A pharmacist-managed cardiovascular risk-reduction clinic for individuals experiencing serious mental illness"],"prefix":"10.1016","volume":"59","author":[{"given":"Jasmine D.","family":"Gonzalvo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jay A.","family":"Hamm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mu","family":"Shan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.japh.2019.06.012_bib1","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1111\/acps.12431","article-title":"Promoting physical health for people with schizophrenia by reducing disparities in medical and dental care","volume":"132","author":"Moore","year":"2015","journal-title":"Acta Psychiatr Scand"},{"key":"10.1016\/j.japh.2019.06.012_bib2","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1002\/j.2051-5545.2011.tb00014.x","article-title":"Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care","volume":"10","author":"de Hert","year":"2011","journal-title":"World Psychiatry"},{"key":"10.1016\/j.japh.2019.06.012_bib3","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1176\/ps.2006.57.10.1482","article-title":"Mortality and medical comorbidity among patients with serious mental illness","volume":"57","author":"Miller","year":"2006","journal-title":"Psychiatr Serv"},{"key":"10.1016\/j.japh.2019.06.012_bib4","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1038\/npp.2010.78","article-title":"Antipsychotics associated with the development of type 2 diabetes in antipsychotic-na\u00efve schizophrenia patients","volume":"35","author":"Nielsen","year":"2010","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.japh.2019.06.012_bib5","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1176\/ps.2007.58.4.536","article-title":"Quality of diabetes care among adults with serious mental illness","volume":"58","author":"Goldberg","year":"2007","journal-title":"Psychiatr Serv"},{"key":"10.1016\/j.japh.2019.06.012_bib6","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1176\/appi.ps.55.8.892","article-title":"A\u00a0comparison of type 2 diabetes outcomes among persons with and without severe mental illness","volume":"55","author":"Dixon","year":"2004","journal-title":"Psychiatr Serv"},{"key":"10.1016\/j.japh.2019.06.012_bib7","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/j.1945-1474.2011.00155.x","article-title":"Quality of care for cardiovascular disease and diabetes amongst individuals with serious mental illness and those using antipsychotic medications","volume":"34","author":"Scott","year":"2012","journal-title":"J\u00a0Healthc Qual"},{"key":"10.1016\/j.japh.2019.06.012_bib8","doi-asserted-by":"crossref","first-page":"304","DOI":"10.4088\/JCP.08m04718yel","article-title":"Cardiovascular disease mortality in patients with chronic schizophrenia treated with clozapine: a retrospective cohort study","volume":"71","author":"Kelly","year":"2010","journal-title":"J\u00a0Clin Psychiatry"},{"issue":"3","key":"10.1016\/j.japh.2019.06.012_bib9","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/S0165-1781(01)00234-7","article-title":"Estimating the consequences of anti-psychotic induced weight gain on health and mortality rate","volume":"101","author":"Fontaine","year":"2001","journal-title":"Psychiatry Res"},{"key":"10.1016\/j.japh.2019.06.012_bib10","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/S0278-5846(01)00266-4","article-title":"Studies on modulation of feeding behavior by atypical antipsychotics in female mice","volume":"26","author":"Kaur","year":"2002","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"10.1016\/j.japh.2019.06.012_bib11","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1097\/JCP.0000000000000261","article-title":"Association study of GABAA \u03b12 receptor subunit gene variants in antipsychotic-associated weight gain","volume":"35","author":"Zai","year":"2015","journal-title":"J\u00a0Clin Psychopharmacol"},{"issue":"2","key":"10.1016\/j.japh.2019.06.012_bib12","first-page":"596","article-title":"American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, and North American Association for the Study of Obesity consensus development conference on antipsychotic drugs and obesity and diabetes","volume":"27","year":"2004","journal-title":"Diabetes Care"},{"key":"10.1016\/j.japh.2019.06.012_bib13","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.psychres.2014.04.028","article-title":"Mental health stigma and primary care decisions","volume":"218","author":"Corrigan","year":"2014","journal-title":"Psychiatry Res"},{"key":"10.1016\/j.japh.2019.06.012_bib14","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1176\/appi.ps.55.12.1434","article-title":"Community pharmacists\u2019 attitudes toward and professional interactions with users of psychiatric medication","volume":"55","author":"Phokeo","year":"2004","journal-title":"Psychiatr Serv"},{"key":"10.1016\/j.japh.2019.06.012_bib15","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1097\/NMD.0b013e3182349fea","article-title":"Long-term glucose control among type 2 diabetes patients with and without severe mental illness","volume":"199","author":"Brown","year":"2011","journal-title":"J\u00a0Nerv Ment Dis"},{"key":"10.1016\/j.japh.2019.06.012_bib16","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.psychres.2017.01.049","article-title":"Are people with schizophrenia adherent to diabetes medication? A comparative meta-analysis","volume":"250","author":"Gorczynski","year":"2017","journal-title":"Psychiatry Res"},{"key":"10.1016\/j.japh.2019.06.012_bib17","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1176\/appi.ps.201300118","article-title":"Adherence to oral diabetes medications among users and nonusers of antipsychotic medication","volume":"65","author":"Desai","year":"2004","journal-title":"Psychiatry Serv"},{"key":"10.1016\/j.japh.2019.06.012_bib18","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.psychres.2011.03.013","article-title":"A\u00a0comparison of adherence to hypoglycemic medications between type 2 diabetes patients with and without serious mental illness","volume":"188","author":"Kreyenbuhl","year":"2011","journal-title":"Psychiatry Res"},{"issue":"2","key":"10.1016\/j.japh.2019.06.012_bib19","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1331\/108658003321480713","article-title":"The Asheville Project: long-term clinical and economic outcomes of a community pharmacy diabetes care program","volume":"43","author":"Cranor","year":"2003","journal-title":"J\u00a0Am Pharm Assoc (Wash)"},{"issue":"10","key":"10.1016\/j.japh.2019.06.012_bib20","doi-asserted-by":"crossref","first-page":"877","DOI":"10.2146\/ajhp120238","article-title":"Enhancing diabetes care by adding a pharmacist to the primary care team","volume":"70","author":"Ip","year":"2013","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.japh.2019.06.012_bib21","author":"Cowart"},{"issue":"5","key":"10.1016\/j.japh.2019.06.012_bib22","first-page":"423","article-title":"The effect of clinical pharmacist-led comprehensive medication management on chronic disease state goal attainment in a patient-centered medical home","volume":"24","author":"Prudencio","year":"2018","journal-title":"J\u00a0Manag Care Spec Pharm"},{"key":"10.1016\/j.japh.2019.06.012_bib23","doi-asserted-by":"crossref","first-page":"229","DOI":"10.2146\/ajhp070266","article-title":"Development and outcomes of a psychiatric pharmacy clinic for indigent patients","volume":"65","author":"Caballero","year":"2008","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.japh.2019.06.012_bib24","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1093\/ajhp\/59.16.1518","article-title":"Impact of a collaborative pharmacy practice model on the treatment of depression in primary care","volume":"59","author":"Finley","year":"2002","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.japh.2019.06.012_bib25","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1592\/phco.23.15.1634.31952","article-title":"Evaluating the impact of pharmacists in mental health: a systematic review","volume":"23","author":"Finley","year":"2003","journal-title":"Pharmacotherapy"},{"issue":"1","key":"10.1016\/j.japh.2019.06.012_bib26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.9740\/mhc.2015.01.001","article-title":"Improving medication-related outcomes for patients with psychiatric and neurologic disorders: value of psychiatric pharmacists as part of the health care team","volume":"5","author":"Goldstone","year":"2015","journal-title":"Ment Health Clin"},{"key":"10.1016\/j.japh.2019.06.012_bib27","doi-asserted-by":"crossref","first-page":"313","DOI":"10.2337\/cd17-0041","article-title":"Clinical application of patient-centered diabetes care for people with serious mental illness","volume":"35","author":"Hamm","year":"2017","journal-title":"Clin Diabetes"},{"key":"10.1016\/j.japh.2019.06.012_bib28","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1136\/bmj.321.7258.405","article-title":"Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study","volume":"321","author":"Stratton","year":"2000","journal-title":"BMJ"},{"issue":"1","key":"10.1016\/j.japh.2019.06.012_bib29","first-page":"S90","article-title":"Standards of medical care in diabetes\u20142019","volume":"42","year":"2019","journal-title":"Diabetes Care"}],"container-title":["Journal of the American Pharmacists Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1544319119302900?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1544319119302900?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T05:46:24Z","timestamp":1761543984000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1544319119302900"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9]]},"references-count":29,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["S1544319119302900"],"URL":"https:\/\/doi.org\/10.1016\/j.japh.2019.06.012","relation":{},"ISSN":["1544-3191"],"issn-type":[{"value":"1544-3191","type":"print"}],"subject":[],"published":{"date-parts":[[2019,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A pharmacist-managed cardiovascular risk-reduction clinic for individuals experiencing serious mental illness","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Pharmacists Association","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.japh.2019.06.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 American Pharmacists Association\u00ae. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}